---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-062421"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:09:41.036073+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Axsome Q4 revenue $196M (+65% YoY); AXS-05 PDUFA set for April 30, 2026

## Summary
- Total net product revenue Q4 $196.0M, FY $638.5M (+66% YoY); AUVELITY sales $507.1M (+74%).
- Net loss Q4 $28.6M ($0.56/share), FY $183.2M ($3.68); cash $322.9M; operating loss narrowed.
- sNDA for AXS-05 (Alzheimer's agitation) granted Priority Review, PDUFA target April 30, 2026.
- SUNOSI generic patent litigation with Alkem settled; license delays generic entry until 2040.
- Acquired AXS-17 (GABA A PAM) for epilepsy; NDA submission for AXS-12 narcolepsy expected Q1 2026.

## SEC filing metadata
- accession: 0001193125-26-062421
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/0001193125-26-062421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-20260223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-062421
- JSON: https://secwatch.observer/filing/0001193125-26-062421.json
- Plain text: https://secwatch.observer/filing/0001193125-26-062421.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.